Annals of Internal Medicine 观察性研究:口服 semaglutide 减肥处方早期采用速度显著快于注射剂
Early uptake for oral semaglutide proves rapid relative to injectables
Johns Hopkins 团队基于 2020 年 7 月至 2026 年 6 月的全国处方数据,分析口服 semaglutide(Wegovy pill)的早期采用情况。
基于真实世界处方数据,量化了口服药物相对注射剂的早期采用速度及市场影响。
Early uptake was rapid for oral semaglutide (Wegovy pill) relative to injectable incretin-based weight management therapies, according to a study published online Oct. 13 in Annals of Internal Medicine.
Yara Jelwan, M.D., M.P.H., from Johns Hopkins Ciccarone Center for Cardiovascular Disease Prevention in Baltimore, and colleagues examined uptake of oral semaglutide for obesity management using monthly national prescription data from the IQVIA National Prescription Audit. Analyses were restricted to branded weight management therapies: Wegovy pill, injectable semaglutide (Wegovy), and injectable tirzepatide (Zepbound). Monthly filled new prescriptions were assessed from July 2020 through June 2026.
The researchers found that prescriptions for weight management therapies increased rapidly over time; after introduction of the Wegovy pill, there was continued growth in injectable Wegovy and Zepbound prescriptions. Rapid early uptake of the Wegovy pill was seen, exceeding 100,000 new prescriptions by the second month after launch. The steepest early adoption curve was seen for the Wegovy pill in launch-aligned analyses, with an early uptake slope that was about 4.4- and 7.4-fold steeper than for Zepbound and injectable Wegovy, respectively.
The number of prescriptions for injectable Wegovy did not decrease after introduction of the Wegovy pill, but additional prescription growth was contributed by the Wegovy pill, yielding an increase in total semaglutide weight management prescriptions over time. After introduction of oral Wegovy in January 2026, the combined number of Wegovy prescriptions increased, with oral Wegovy accounting for much of the net increase.
"These findings may not be durable over time and should be interpreted within a rapidly evolving therapeutic landscape," the authors write.
One author disclosed ties to the pharmaceutical industry.
Publication details
Yara Jelwan et al., Early Uptake of Oral Semaglutide for Obesity Treatment After Regulatory Approval, Annals of Internal Medicine (2026). DOI: 10.7326/annals-26-02436
Journal information: Annals of Internal Medicine
Key medical concepts
Who's behind this story?
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Copyright © 2026 HealthDay. All rights reserved.
Citation: Early uptake for oral semaglutide proves rapid relative to injectables (2026, October 22) retrieved 22 October 2026 from https://medicalxpress.com/news/2026-10-early-uptake-oral-semaglutide-rapid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com